Onvatilimab is a human monoclonal antibody that targets VISTA (V-domain immunoglobulin suppressor of T-cell activation). Onvatilimab inhibits VISTA signaling, abrogates the VISTA-induced suppression of T-lymphocyte-mediated immune responses, enhances cytotoxic T-cell responses against tumor cells and inhibits tumor cell growth.